A Multicentre Open-label Two-arm Randomised Superiority Clinical Trial of Azithromycin Versus Usual Care In Ambulatory COVID19 (ATOMIC2)

COVID-19 Clinical Trial

— ATOMIC2  

Official title:

A Multi-centre Open-label Two-arm Randomised Superiority Clinical Trial of Azithromycin Versus Usual Care In Ambulatory COVID-19 (ATOMIC2)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04381962
• Other study ID #: ATOMIC2
• Secondary ID: 2020-001740-2628
• Status: Completed
• Phase: Phase 3
• Start date: June 3, 2020
• Est. completion date: April 20, 2021

Study information

• Verified date: May 2020
• Source: University of Oxford
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A multi-centre open-label two-arm randomised superiority clinical trial of two weeks of oral Azithromycin 500mg once daily versus usual care in adult patients presenting to secondary care with clinically-diagnosed COVID-19 but assessed as appropriate for initial ambulant (outpatient) management, in preventing progression to respiratory failure or death.

Description:

Hypothesis: Use of Azithromycin 500 mg once daily for 14 days is effective in preventing and/or reducing the severity of lower respiratory illness of COVID-19 disease at 28 days.

Study design: Multi centre, prospective open label two-arm randomised superiority clinical trial of standard care and Azithromycin with standard care alone for those presenting to hospital with COVID-19 symptoms who are not admitted at initial presentation.

Study setting: Patients being assessed by secondary care NHS hospitals in the UK.

Participants: Adults, ≥18 years of age assessed in an acute hospital with clinical diagnosis of COVID-19 infection and where medically it is decided not to admit the patient and for the patient to be managed on an ambulatory (outpatient) care pathway at their usual residence (home or care home).

Study schedule: Enrolment on day 0. Telephone follow up at day 14 day, and day 28. If admitted between randomisation and day 28, data will be collected until hospital discharge.

Intervention: Azithromycin 500 mg orally once daily for 14 days. The first dose will be within 4 hours of randomisation. This is in addition to standard care as per local hospital advice for those patients with suspected COVID who are not admitted: i.e. symptomatic relief with rest, as-required paracetamol (where appropriate) and advice to seek further medical attention if significant worsening of breathlessness.

Comparator: Standard care as per local hospital advice for those patients with suspected COVID who are not admitted: i.e. symptomatic relief with rest, as-required paracetamol (where appropriate) and advice to seek further medical attention if significant worsening of breathlessness.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 298
• Est. completion date: April 20, 2021
• Est. primary completion date: January 29, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years and older

Eligibility

Inclusion Criteria:

• Male or Female, aged at least 18 years

• Assessed by the attending clinical team as appropriate for initial ambulatory (outpatient) management

• A clinical diagnosis of highly-probable COVID-19 infection (diagnosis by the attending clinical team)

• No medical history that might, in the opinion of the attending clinician, put the patient at significant risk if he/she were to participate in the trial

• Able to understand written English (for the information and consent process) and be able to give informed consent

Exclusion Criteria:

• Known hypersensitivity to any Macrolide including Azithromycin, Ketolide antibiotic, or the excipients including an allergy to soya or peanuts.

• Known fructose intolerance, glucose-galactose malabsorption or sucrose-isomaltase-insufficiency

• Currently on a Macrolide antibiotic (Clarithromycin, Azithromycin, Erythromycin, Telithromycin, Spiramycin)

• On any SSRI (Selective Serotonin Reuptake Inhibitor)

• Elevated cardiac troponin at initial assessment suggestive of significant myocarditis (if clinically the clinical team have felt it appropriate to check the patient's troponin levels)

• Evidence of QTc prolongation: QTc>480ms

• Significant electrolyte disturbance (e.g. hypokalaemia K+<3.5 mmol/L)

• Clinically relevant bradycardia (P<50 bpm), non-sustained ventricular tachycardia or unstable severe cardiac insufficiency

• Currently on hydroxychloroquine or chloroquine

Related Conditions & MeSH terms

• COVID-19

Intervention

Drug:
• Azithromycin Capsule
Azithromycin 500 mg OD PO 14 days

Locations

Country	Name	City	State
United Kingdom	Horton General Hospital	Banbury	Oxfordshire
United Kingdom	Birmingham City Hospital	Birmingham
United Kingdom	Ninewells Hospital	Dundee	Scotland
United Kingdom	John Radcliffe Hospital	Oxford	Oxfordshire
United Kingdom	Sandwell General Hospital	West Bromwich

Sponsors (2)

Lead Sponsor	Collaborator
University of Oxford	Pfizer

Country where clinical trial is conducted

United Kingdom, 

References & Publications (1)

Hinks TSC, Barber VS, Black J, Dutton SJ, Jabeen M, Melhorn J, Rahman NM, Richards D, Lasserson D, Pavord ID, Bafadhel M. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial. Trials. 2020 Aug 17;21(1):718. doi: 10.1186/s13063-020-04593-8. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Mechanistic analysis of blood and nasal biomarkers if available	The following samples may be taken. Blood for serum, Tempus tube (whole blood RNA), EDTA tubes (PBMC), nasal brush to be placed immediately into RNA lysis buffer (for subsequent PCR and transcriptomic analysis). Includes assessment of mycoplasma prevalence for subgroup analysis.	Samples to be collected prospectively at baseline and again if patient admitted, to be taken as soon as possible and within 72 hours of admission if possible.
Primary	Proportion progressing to respiratory failure or death (all clinically-diagnosed participants)	Efficacy will be determined through differences in the proportion with either death or admission with respiratory failure requiring level 2 ventilation (NIV/CPAP/nasal high-flow) or level 3 (invasive mechanical ventilation) in the 28 days from randomisation.	Determined at day 28 from randomisation.
Secondary	Proportion progressing to respiratory failure or death (SARS-CoV-2 PCR positive)	Efficacy will be determined through differences in the proportion with either death or admission with respiratory failure requiring level 2 ventilatory support (NIV/CPAP/nasal high-flow) or level 3 (invasive mechanical ventilation) in the 28 days from randomisation using a retrospective analysis of COVID-19 oropharyngeal swabs for those who had one taken at time of randomisation.	Determined at day 28 from randomisation.
Secondary	All cause mortality	Data on vital status (alive / dead, with date and presumed cause of death if appropriate)	Ascertain data at 28 days after randomisation.
Secondary	Proportion progressing to pneumonia.	Progression to pneumonia as diagnosed by chest x-ray (or CT thorax), with compatible clinical findings, if no pneumonia is present at time of enrolment. To be diagnosed by a medically qualified doctor and data obtained from review of case-notes and relevant radiology.	Ascertain this information at time of pneumonia diagnosis, or at 28 days after randomisation (whichever is sooner)
Secondary	Proportion progressing to severe pneumonia	Evolution of pneumonia, as diagnosed by chest x-ray or CT thorax, if pneumonia is present at time of enrolment. To be diagnosed by a medically qualified doctor and data obtained from review of case-notes and relevant radiology. Severe pneumonia is defined as BTS CURB-65 score of 3-5.	Ascertain this information at time of pneumonia diagnosis, or at 28 days after randomisation (whichever is sooner)
Secondary	Peak severity of illness	The 9-point ordinal scoring system is described in the protocol reflects the severity of respiratory illness. The maximum severity score during the entire study period will be compared.	Ascertain from day 14 and day 28 telephone call and from retrospective ePR/medical notes data at 28 days after randomisation.
Secondary	Safety and tolerability	Serious adverse events and concomitant medications. Record at enrolment, emergently during study period and proactively elicit at day 14 and at day 28.	Emergent data collection days 0-28 and elicit proactively at day 14 and day 28 post randomisation.

External Links

•   ATOMIC2 homepage